FDA Brief

Warning letters Drugs

FDA warning letter to

Owen Biosciences, Inc.

High riskIssued Oct 30, 2025Posted Nov 25, 2025Center for Drug Evaluation and Research (CDER)

Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.

What happened

FDA inspected Owen Biosciences' drug manufacturing facility in Baton Rouge, LA, from March 25 to 27, 2025. FDA found the firm did not establish adequate laboratory controls or test each batch before release, including no benzene testing on benzoyl peroxide OTC products; FDA's lab found more than 20 parts per million (ppm) benzene in one lot of 2.5% benzoyl peroxide acne lotion. FDA also found an inadequate stability program and inadequate quality unit oversight, and the firm and distributor did not recall the tested lot before it expired.

What FDA found

  1. The firm lacked scientifically sound specifications and final batch laboratory testing before release, and it did not test benzoyl peroxide products for benzene; FDA found more than 20 ppm benzene in one lot.

    21 CFR 211.160(b) and 211.165(a)
  2. The firm's stability program was inadequate: full shelf-life studies were not done, and testing lacked identity, microbiological, and impurity tests.

    21 CFR 211.166(a)
  3. The quality control unit did not adequately oversee manufacturing, including batch record review, investigation of discrepancies, change control, and annual product review.

    21 CFR 211.22, 211.192, 211.180(e)
  4. After FDA recommended removal, the distributor said it would voluntarily recall the tested lot, but neither Owen nor the distributor recalled it before expiration.

What FDA wants

FDA tells Owen to respond in writing within 15 working days with corrective actions and supporting information. It asks for product specifications and test methods, a benzene test method, retain-sample testing and risk actions, a stability-program assessment and correction plan, an independent lab-system assessment, quality unit improvements, and a qualified current good manufacturing practice (CGMP) consultant.

Who should pay attention

  • brands and distributors selling Owen-made OTC acne products
  • contract manufacturers of OTC topical drugs
  • quality and recall teams handling benzoyl peroxide products

This is a summary. Read the original letter on fda.gov.

Owen Biosciences, Inc.'s FDA history

Recalls in the last 12 months

Apr 22 Class II Owen Biosciences Inc.
Drug
FHF Farmhouse Fresh, Midnight Clearing, NIGHT LOTION, 2.5% BENZOYL PEROXIDE ACNE TREATMENT, OTC a) 0.5 fl. oz./15ml; and b)1 fl. oz./30ml tubes; Made in the USA for FarmHouse Fresh, 8797 CR 858 McKinney, Texas
Chemical contamination: Presence of benzene
Apr 22 Class II Owen Biosciences Inc.
Drug
SLMD BP Acne Spot Treatment, 10% Benzoyl Peroxide, 0.5 fl. oz - 15 mL bottles, Sandra Lee MD, Distributed by Skin PS Brands, Culver City, CA90232.
Chemical contamination: Presence of benzene
Apr 22 Class II Owen Biosciences Inc.
Drug
SLMD Benzoyl Peroxide Acne Lotion, Benzoyl Peroxide 2.5%, a) 0.7 fl. oz - 21 mL and b) 1.5 fl. oz. - 44mL bottles, SANDRA LEE MD., Distributed by Skin PS Brands, Culver City, CA 90232.
Chemical contamination: Presence of benzene
Apr 22 Class II Owen Biosciences Inc.
Drug
HydroPeptide CLEAR ALLIANCE SERUM, 2.5% BENZOYL PEROXIDE, a)1 FL OZ/30ml; b) 2 FL OZ/60ml spray bottle; DIST BY HYDROPEPTIDE LLC, ISSAQUAH, WA 98027
Chemical contamination: Presence of benzene

Full company page